#MeToo: Raghu Dixit accused of misbehaving with female singer

Paris, Jan 24: Rahul Mishra and Imane Ayissi made history on Thursday by becoming the first Indian and black African designers to show their clothes on the elite Paris haute couture catwalk.

Only a little more than a dozen of the world's most prestigious luxury labels -- including Dior, Chanel and Givenchy -- have a right to call their clothes haute couture.

All the clothes must be handmade -- and go on to sell for tens of thousands of euros (dollars) to some of the richest and most famous women in the world.

Mishra, an advocate of ethical "slow fashion" who blames mechanisation for much of the world's ills, said "it felt amazing and very surreal to be the first Indian to be chosen." "They see a great future for us -- which will make us push ourselves even harder," the 40-year-old told AFP after his debut show was cheered by fashionistas.

Both Mishra and Cameroon-born Ayissi, 51, are champions of traditional fabrics and techniques from their homelands and are famous for their classy lines.

Ayissi said his selection was "immense" both for Africa and himself.

"I am so proud that I can show my work and showcase real African fabrics and African heritage," he told AFP backstage as celebrities, including the chic head of Unesco, Audrey Azoulay, congratulated him.

Mishra broke through on the Paris ready-to-wear scene after winning the International Woolmark Prize in 2014, the top award that also launched the careers of such greats as Karl Lagerfeld and Yves Saint Laurent.

The purity of his often white creations with their detailed but understated embroidery has won him many fans, including Vogue's legendary critic Suzy Menkes.

The doyenne of fashion's front row called him an Indian "national treasure".

But this time, Mishra turned up the colour palette somewhat with dresses that subtly evoked the jungle paradises and pristine underwater world off the Maldives he worries that one day we might lose.

Appalled by the smoke and pollution that meant he had to keep his four-year-old daughter indoors in Delhi for nearly 20 days in November, Mishra said he imagined a "pure virginal and untamed planet... with ecosystems crafted out of embroidered flora and fauna".

"I am very emotional about it. Sometimes it makes me cry. All our children should be growing up in a better world," he added.

"When I take Aarna (his daughter) to the foothills of the Himalayas and the sky turns blue, she is so happy.

"Once, when she saw the River Ganges, she said: 'Can you please clean it for us so can go for a swim?'"

Mishra said he was reducing the quantity of clothes he was producing while at the same time increasing their quality, with humming birds, koalas and other animals hidden in the hundreds of hand worked embroidered leaves and flowers of his "jungle dresses".

The designer has won ethical and sustainability awards for his work supporting local crafts people in rural India.

"My objective is to create jobs which help people in their own villages," Mishra said.

"If villages are stronger, you will have a stronger country, a stronger nation, and a stronger world," he added.

Ayissi takes a similar stand, refusing to use wax prints popular in West Africa which he dismisses as "colonial".

Dutch mills flooded Africa with cotton printed with colourful patterns borrowed from Indonesian batik in the 19th century, and still dominate the market.

"When we talk about African fashion, it's always wax, which is a real pity," he told AFP, "because it's killing our own African heritage."

Ayissi, a former dancer who worked with singers such as Sting and Seal, told AFP he wanted to open up "a new path for Africa" and find an "alternative way of doing luxury fashion".

He has gone back to using prestigious local materials, like the strip fabric kente woven by the Akan people of Ghana and the Ivory Coast, which was originally worn only by nobles.

The son of an undefeated African boxing champ and a former Miss Cameroon, he also uses appliqued techniques from Benin and Ghana.

Haute couture shows only take place in Paris and the criteria to enter and remain in fashion's elite club are strictly enforced by French law.

Mumbai, Jan 7: Actor Anil Kapoor, who next will be seen onscreen in Malang, revealed that he always tells superstar Aamir Khan not to stop working with filmmaker Rajkumar Hirani.

Kapoor was interacting with the media at the trailer launch of Malang along with his co-actors Adtiya Roy Kapur, Disha Patani, Elli AvRam, film's director Mohit Suri and producers Luv Ranjan, Bhushan Kumar, Ankur Garg and Jay Shewakraman on Monday in Mumbai.

Anil Kapoor has worked with many directors and producers in his 40-year acting career.

Talking about camp culture in the Hindi film industry and praising makers of Malang, Kapoor said, "I feel we need producers like Ankur (Garg) and Luv (Ranjan). I have told Mohit (Suri) to continue doing films with them. I always tell Aamir Khan by calling him on the phone to say that you should not leave Raju Hirani (Rajkumar Hirani). Whenever I see films of both of them, I tell Aamir not to leave him."

He continued, "I feel whenever you make a good team then you should hold on to it. Team is very important and there are certain stars that come together to make something interesting and exciting."

Kapoor gave an example of Hollywood actors and filmmakers while backing his viewpoint.

"If you see Martin Scorsese, Robert De Niro, Leonardo DiCaprio they do so many films together. They can work with others, too, but they keep working with each other. There is some magic, obviously. You have to go with the casting but somewhere I feel teams should stand by each other," the actor added.

Malang stars Aditya Roy Kapur, Disha Patani, Anil Kapoor and Kunal Khemu in lead roles. It is scheduled to release on February 7.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.